Planet Green bets on lactoferrin's supply squeeze to break into China's health market
China imports nearly all of the lactoferrin it consumes, a supply gap that stems from limited domestic production capacity. Against that backdrop, Planet Green Holdings Corp. (NYSE American: PLAG), a Flushing, New York-based…
Key takeaways
- Planet Green Holdings Corp. (NYSE American: PLAG) announced on August 11, 2026 that it has entered commercial operations to source, market, and distribute lactoferrin for the Chinese market.
- China imports nearly all the lactoferrin it consumes due to limited domestic production capacity, creating the supply gap Planet Green is targeting.
- China accounts for an estimated 22% of global lactoferrin demand in a market the company pegged at roughly $300 million annually and growing about 9% per year.
- Planet Green cited projections that Chinese lactoferrin sales could exceed $100 million by 2030 and global demand could reach $500 million.
- The company plans to hire a Chief Scientist and has a candidate at a leading US academic institution in advanced-stage negotiations.
China imports nearly all of the lactoferrin it consumes, a supply gap that stems from limited domestic production capacity. Against that backdrop, Planet Green Holdings Corp. (NYSE American: PLAG), a Flushing, New York-based holding company with operations across mainland China and Canada, announced on August 11, 2026 that it has entered commercial operations to source, market, and distribute lactoferrin, targeting the Chinese market with an ingredient the company already uses in its own chewable immune tablets.
Why supply shapes the market
Commercially produced lactoferrin reaches buyers through two methods. The dominant approach extracts it from bovine milk using membrane filtration and ion-exchange chromatography. Because milk contains relatively little lactoferrin, the process requires large volumes, making production expensive and supply-constrained. A second method, precision fermentation, uses genetically engineered microorganisms to produce recombinant lactoferrin in fermentation tanks and offers greater scalability, but commercial adoption remains at an early stage. The cost profile and scarcity of the bovine-derived compound underpin its trade name, "Pink Gold," a term Planet Green cited in its August 11 announcement.
The China read-through
China accounts for an estimated 22% of global lactoferrin demand, against a market the company pegged at approximately $300 million annually. The compound goes into infant formula and sports nutrition products, among other supplement categories, all of which are expanding in China. The broader market is growing at an estimated 9% per year, and Planet Green cited projections that Chinese sales alone could exceed $100 million by 2030, with global demand potentially reaching $500 million. Chief executive Zhou Bin said the company's access to pure, high-quality lactoferrin, which he described as unavailable to most Chinese manufacturers, should strengthen its market position.
Planet Green operates a diversified portfolio spanning consumer products and online advertising, and the lactoferrin move is its bid to concentrate more revenues around health ingredients. To support product development, the company said it plans to hire a Chief Scientist. It has identified a candidate at a leading US academic institution, with negotiations described as at an advanced stage.
The read-through for investors carries a real caveat. Lactoferrin supply is tied to global dairy processing volumes, and Planet Green has no direct control over that input. Entry into a constrained market is contingent on access the company has arranged but does not produce.
Related reading
Source · 來源